Potentially dilutive shares of common stock were excluded
from the computation of diluted shares outstanding for the three months ended March 31, 2025, and 2024 as they would have an anti-dilutive
impact on the Company’s net losses in that period and consisted of the following:
SCHEDULE
OF POTENTIALLY DILUTIVE SHARES EXCLUDED FROM COMPUTING OF DILUTED SHARES OUTSTANDING
| | |
March 31, 2025 | | |
March 31, 2024 | |
| Stock warrants | |
| 945,353,089 | | |
| 948,403,679 | |
| Stock options | |
| - | | |
| 80,000 | |
| Series E convertible preferred stock | |
| 95,238,667 | | |
| 95,238,667 | |
| Series G convertible preferred stock | |
| 2,032,500,000 | | |
| 2,153,315,000 | |
| Series H convertible preferred stock | |
| 323,740,000 | | |
| 323,740,000 | |
| Antidilutive securities
excluded from computation of earnings per share | |
| 3,396,831,756 | | |
| 3,520,777,346 | |
|